# ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

> **NCT05656508** · PHASE1 · COMPLETED · sponsor: **Laboratorio Pablo Cassara S.R.L.** · enrollment: 80 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)

## Key facts

- **NCT ID:** NCT05656508
- **Lead sponsor:** Laboratorio Pablo Cassara S.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-20
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-10-29
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656508, "ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05656508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*